- Fresenius saw adjusted net income rise 24% in Q1 due to new generic drugs and supply issues at rivals. Fresenius Medical Care confirmed 15-20% net income growth target for the year after Q1 net income rose 9%. - Grifols' Q1 net revenues increased 5.6% to $1.1 billion, with recurring sales up 7.1%. Novo Nordisk plans to meet all of Russia's insulin demand in coming years. - Sanofi said it will try to replace Medivation's board if it does not engage in takeover talks. Smith & Nephew reported 3% revenue growth in Q1 and backed full-year guidance.

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
Fresenius saw adjusted net income rise 24% to $417 million in the first quarter, bolstered by the
launch of new generic infusion drugs and rivals' supply shortages. (reuters.com)
Fresenius Medical Care confirmed it was targeting 15 to 20 net income growth this year, adjusted for
one-off items. Its Q1 net income rose 9% to $228 million. (reuters.com)
Grifols increased its net revenues for the first quarter of 2016 by 5.6% (+1.5% constant currency) to
$1.1 billion. Recurring sales grew by 7.1% (excl. raw materials and others). (thepharmaletter.com)
Novo Nordisk plans to meet the entire demand of Russia for insulin over next few years, according to
Kenneth Mortensen, vice president of Novo Nordisk. (thepharmaletter.com)
Sanofi said it sent a letter to Medivation Inc. saying it would try to remove and replace members of
the U.S. biotech firm's board if it didn't engage in takeover talks. (marketwatch.com)
Smith & Nephew reported first-quarter revenue of $1.14 billion, up 3% on the same period last year,
and backed its full-year guidance. (marketwatch.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 10
2016-05-08
AbbVie Allergan Astellas Cochlear Daiichi Sankyo Fresenius Fresenius Medical Care
Grifols Johnson & Johnson Medtronic Novo Nordisk Sanofi Smith & Nephew Valeant
SPOTLIGHT
COMPANY NEWS
AbbVie has expanded its cystic fibrosis deal with Galapagos, positioning the Belgian biotech to
pocket $250 million more than under the original agreement. (fiercebiotech.com)
Allergan announced positive news as it received FDA approval and soon launches the first generic
version of crestor (rosuvastatin). (reuters.com)
Johnson & Johnson is appealing two recent jury verdicts awarding a total of $127 million to women
ho la e their o aria a er o tal i the o pa y’s i o i a y po der. (wsj.com)
Medtronic has hired Karen L. Parkhill as its new chief financial officer, recruiting her from the same
role at Comerica Inc. She will start her new position on June 20. (wsj.com)
Valeant, which has come under fire from politicians because of dramatic price increases for its drugs,
said it had formed a committee that will be responsible for those prices going forward. (wsj.com)
Astellas promoted Mark Wanda to executive director, anti-bribery and anti-corruption, while Nahrin
Marino and Matt Silversten have taken on the role of deputy general counsels. (pmlive.com)
Cochlear implants might take an innovative leap as New York University researchers developed an
algorithm for noise reduction which helps tackle babble signals. (news-medical.net)
Daiichi Sankyo announced the outcome of the arbitration proceeding with Ranbaxy, that has to pay
Daiichi Sankyo $512 million as compensatory damages and interest. (reuters.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
96%
98%
100%
102%
2016-05-02 2016-05-03 2016-05-04 2016-05-05 2016-05-06
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
This week’s sto k perfor a e of the world’s iggest listed health are o pa ies shows a negative
development of -1.3% while their one year change reaches -9.2%. Main driver was the European
region with -3.1% on a weekly basis and -14.4% on a yearly basis. Asia/Pacific decreased by -1.5% and
North America declined by -0.6%. The respective one year performance is +11.0% and -9.0%.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 10
2016-05-08
BB Biotech Grifols Indivior Recordati Shire
Sonova Stada Straumann Swedish Orphan William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
Taki g a look at Europe’s top perfor er this week, the ost striki g a didate is Straumann, gaining
+7.9% on a weekly basis while its one year performance reaches +32.7%. Second winner from Europe
is Stada with a gain of +7.3% this week, whereas its one year change amounts to +23.3%.
Regarding the lower end of the weekly performance ranking, Swedish Orphan takes the lead due to
its decline of -6.9% compared to its one year change of -20.3%. Next is Indivior, suffering from a
decrease of -4.8% this week and facing a one year performance of -33.1%.
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
690.05 -3.15% -14.39% 713.68 688.44 876.66 654.95
STOXX® North America 600
Health Care
794.35 -0.63% -8.99% 801.56 788.56 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
433.40 -1.51% +10.97% 433.40 428.95 454.36 349.32
STOXX® Global 1800
Health Care
698.07 -1.30% -9.18% 706.50 694.34 842.76 647.94
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Swedish Orphan 107.62 -6.95% -20.34% 119.10 105.75 143.22 93.75
Indivior 151.20 -4.85% -33.12% 153.40 137.97 271.40 126.60
BB Biotech 43.92 -4.58% -15.78% 46.87 43.20 62.40 35.50
Shire 51.40 -4.50% -27.50% 54.18 51.24 81.72 43.93
Grifols 18.22 -3.17% +2.18% 19.08 18.22 23.00 17.00
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Straumann 331.01 +7.92% +32.75% 333.42 302.33 333.42 235.15
Stada 39.86 +7.30% +23.26% 40.50 37.16 40.50 28.07
Recordati 22.86 +7.13% +30.66% 22.99 21.74 24.44 17.48
Sonova 121.58 +4.91% -4.86% 123.59 117.18 140.05 100.91
William Demant 89.06 +3.29% +22.67% 91.30 88.94 93.04 66.45